Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup

Today, almost all available birth control options are female contraceptives. Biotech company Contraline, however, claims that clinical trials for its non-hormonal and reversible male contraceptive have reached a critical milestone. In a news release published today, Contraline announced that its male contraceptive, named ADAM, proved to be effective and safe 24 months into its first human clinical trial. While their clinical results have yet to be published in a scientific journal, the company plans to release additional data during the American Urological Association (AUA) meeting on April 26. ADAM is a water-soluble hydrogel injected into the vasa deferentia—the two tubes in men that carry sperm from the testicles to the urethra—via a minor procedure. The implant blocks the sperm while still allowing ejaculation, and Contraline has been marketing it as a future, long-term, reversible alternative to condoms and vasectomies. “Our goal was to create a male contraceptive option lastin ... Read full article.